ReviewNature cancer2021
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment.
Review in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed.
- Microfluidic Biofabrication of a Hydrogel Vessel-Like Structure for Interrogating Tumor Cell Propagation in a Breast Cancer-on-a-Chip Model.Advanced healthcare materials · 2026Article
- Necroptosis triggers inflammatory interferon signatures in patient-derived metastatic breast cancer organoids.Signal transduction and targeted therapy · 2026Article
- Value of intratumoral and peritumoral radiomics based on DCE-MRI in predicting HER2-low and HER2-zero in breast cancer.BMC medical imaging · 2026Article
- Prognostic disclosure in metastatic breast cancer: a scoping review.The oncologist · 2026Article
- Evaluation of Experiences With Ecological Momentary Assessment Among Women With Metastatic Breast Cancer: Qualitative Study.JMIR cancer · 2026Observational
- Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.Nature communications · 2026Article
- Expression Characteristics of PAX7 and Its Prognostic Correlation in Breast Cancer.The breast journal · 2026Article
- Emerging Approaches in Breast Cancer: From Molecular Mechanisms to Diagnosis and Therapeutic Strategies.Oncology research · 2026Review
- Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue.Nature communications · 2025Article
- Integrated spatial proteomic analysis of breast cancer heterogeneity unravels cancer cell phenotypic plasticity.Nature communications · 2025Article
- Tumor-Tissue Boundaries as Instructive Interfaces in Breast Cancer Cell Invasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Multi-omic-based classification for identifying optimal neoadjuvant treatment strategies for high-risk early-stage breast cancer.Science China. Life sciences · 2025Article
- SLB-msSIM: A Spectral Library-Based Multiplex Segmented SIM Platform for Single-Cell Proteomic Analysis.Proteomics · 2025Article
- Role of intratumoral heterogeneity in metastatic progression and drug resistance.Discover oncology · 2025Review
- Natural Compounds as Modulators of Ferroptosis: Mechanistic Insights and Therapeutic Prospects in Breast Cancer.Biomolecules · 2025Review
- SEER-based machine learning prediction of bone metastasis in breast cancer: model development and validation.Gland surgery · 2025Article
- Genome-level selection in tumors as a universal marker of resistance to therapy.Nature communications · 2025Article
- Integrative multimodal ultrasound and radiomics for early prediction of neoadjuvant therapy response in breast cancer: a clinical study.BMC cancer · 2025Article
- Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells.Journal of personalized medicine · 2025Review
- In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancer.Breast cancer research : BCR · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Rational development of targeted therapies has revolutionized metastatic breast cancer outcomes, although resistance to treatment remains a major challenge. Advances in molecular profiling and imaging technologies have provided evidence for the impact of clonal diversity in cancer treatment resistance, through the outgrowth of resistant clones. In this Review, we focus on the genomic processes that drive tumoral heterogeneity and the mechanisms of resistance underlying metastatic breast cancer treatment and discuss implications for future treatment strategies.
Indexed as
Identifiers
35121946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.